PROTECT Study Clouds Travere Therapeutics’ Outlook (Rating Downgrade) (NASDAQ:TVTX)


Navy blue abstract watercolor pattern background. Dark art background for design.

Natalya Bosyak/iStock via Getty Images

At a Glance

In light of new data from the PROTECT study, my previous caution on Travere Therapeutics (NASDAQ:TVTX) has intensified. Filspari’s mixed efficacy—significant in proteinuria reduction but inconclusive in pivotal eGFR total slope—casts doubt on its long-term



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *